News brief­ing: As­traZeneca fol­lows Am­gen down KRAS/SHP2 com­bo path; Val­lon Phar­ma­ceu­ti­cals files for $17 mil­lion IPO 

Rev­o­lu­tion Med­i­cines is adding As­traZeneca to its ros­ter of clin­i­cal col­lab­o­ra­tors, lend­ing its lead drug, RMC-4630, for a study pair­ing it with the phar­ma gi­ant’s KRAS G12C pro­gram.

As­traZeneca will spon­sor and con­duct the study once its now pre­clin­i­cal drug is ready for hu­man stud­ies, an arrange­ment sim­i­lar to the deal Rev­o­lu­tion has with Am­gen on so­tora­sib.

“Drug com­bi­na­tions are like­ly to be crit­i­cal for de­feat­ing in­her­ent drug re­sis­tance mech­a­nisms ex­ploit­ed by RAS-ad­dict­ed can­cers,” CEO Mark Gold­smith said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.